![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PLAVIX LITIGATION SETTLEMENT FAILS TO RECEIVE ANTITRUST CLEARANCE FROM STATES
PLAVIX LITIGATION SETTLEMENT FAILS TO RECEIVE ANTITRUST CLEARANCE FROM STATES
July 31, 2006
Sanofi-aventis and Bristol-Myers Squibb announced that their agreement, as amended, with Apotex Inc. and Apotex Corp., ("Apotex") to settle the patent infringement lawsuit pending between the parties in the U.S. District Court for the Southern District of New York has failed to receive required antitrust clearance from the state attorneys general. The lawsuit relates to the validity
of a composition of matter patent for clopidogrel bisulfate (the '265 patent),
a medicine made available in the United States by sanofi-aventis and Bristol-Myers
Squibb as PLAVIX.
Yahoo
Finance
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct